{"name":"Wen-zhao ZHONG","slug":"wen-zhao-zhong","ticker":"","exchange":"","domain":"","description":"Wen-zhao ZHONG is a biotechnology company focused on developing innovative cancer treatments. The company is advancing a pipeline of immuno-oncology therapies, including Limertinib in combination with chemotherapy and sintilimab, both in Phase 2 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBqQTBPQWNPYld5c2xOVTBZdzNSVGpPM3hONWVjV3ctZGptWWtTMUxHMUJfUmhoQkVGYzRqajRoYW5vaWw0MlRUTnFRdzN0bVlxdnVEY3Z0cDI4bXFIdnZv?oc=5","date":"2023-02-24","type":"trial","source":"Nature","summary":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR -mutant non-small-cell lung cancer: final overall survival analysis of the EMERGING-CTONG 1103 randomised pha","headline":"Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR -mutant non-small-cell lung c","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}